DBV Technologies
29 rue du Faubourg
Saint Jacques
Paris
75014
France
Tel: 33-0-1-55-389270
Fax: 33-0-1-41-312882
Website: http://www.dbv-technologies.com/
Email: info@dbv-technologies.com
190 articles with DBV Technologies
-
DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021
5/5/2021
DBV Technologies, a clinical-stage biopharmaceutical company, announced the filing of its first Form 10-Q for the quarter ended March 31, 2021 with the U.S. Securities and Exchange Commission.
-
DBV Technologies Reports Q1 2021 Financial Results
5/3/2021
DBV Technologies S.A.DBV Technologies S.A.DBV Technologies S.A.DBV Technologies S.A., a clinical-stage biopharmaceutical company, reported financial results for the first quarter of 2021.
-
DBV announced official restructuring plan for keeping the company afloat.
-
DBV Technologies aims to fill the peanut allergy treatment gap, especially for highly allergic children, with their low dose epicutaneous immunotherapy (EPIT) patch Viaskin™ Peanut.
-
In its CRL, the FDA identified concerns regarding the impact of patch-site adhesion on efficacy and indicated the need for patch modifications.
-
DBV Technologies, located just outside Paris, announced it is cutting jobs while it awaits news from the U.S. Food and Drug Administration (FDA) about its application for Viaskin Peanut.
-
BioSpace takes a quick look at some recent, key industry news that is not related to the coronavirus.
-
Clinical Catch-Up: January 6-10, 2020
1/13/2020
The first full business week of the new year began with plenty of clinical trial news. Here’s a look. -
DBV announced positive topline results from its Phase III PEPITES trial evaluating the long-term efficacy and safety of investigational Viaskin Peanut in peanut-allergic children aged 4 to 11 years.
-
Peanut allergy is the most common food allergy in children and that number has been rising – peanut allergy incidence increased 21 percent from 2010 to 2017. Almost 2.5 percent of children in the US are thought to have a peanut allergy, according to the American College of Allergy, Asthma, and Im...
-
BioSpace Global Roundup, Oct. 10
10/10/2019
Companies from across the globe provide updates on their business and pipelines. -
The company withdrew its initial BLA in December after the FDA requested more information regarding manufacturing procedures and quality controls.
-
With the ever-rising concerns over the costs of various prescription medications, a report from consumer pharmaceutical watchdog group Institute for Clinical and Economic Review released a report questioning the potential pricing of two yet-to-be-approved peanut allergy treatments.
-
JAMA Study Shows Viaskin Peanut Offers Clinically Meaningful Desensitization to Peanut
2/23/2019
DBV Technologies Announces Publication of Detailed Phase III Trial Results Evaluating Viaskin Peanut as a Novel Treatment for Peanut Allergy in The Journal of the American Medical Association
-
DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of Peanut-Allergic Children 4 to 11 Years of Age
2/13/2019
DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of Peanut-Allergic Children 4 to 11 Years of Age
-
DBV Technologies Presents Data at ACAAI 2018 on Investigational Viaskin Peanut for the Treatment of Peanut-Allergic Children
11/21/2018
Three oral presentations highlighted analyses from the PEPITES Phase III study
-
An estimated 15 million people in the United States have allergies to more than 170 different foods, according to the non-profit Food Allergy Research and Education. New health data suggests the frequency of food allergies in children under 18 has risen 70 percent since 1997, CNBC reported.
-
French company DBV Technologies is seeing some positive results from its milk allergy treatment.
-
DBV Technologies Provides Update on Regulatory Progress for Viaskin Peanut
2/14/2018
DBV remains on track to submit its BLA in the second half of 2018.
-
Half-Year Report on DBV Technologies Liquidity Contract With Natixis
1/16/2018
As of June 30, 2017, the following assets appeared on the liquidity account: